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Heterozygous STAT1 gain-of-function (GOF) mutations are 
associated with chronic mucocutaneous candidiasis and a broad 
spectrum of infectious, inflammatory, and vascular manifesta-
tions. We describe therapeutic failures with the Janus Kinase 
(JAK) inhibitor ruxolitinib in 2 STAT1 GOF patients with severe 
invasive or cutaneous fungal infections.
Keywords. STAT1; gain of function; ruxolitinib; coccidio-
mycosis; dermatophytosis.
 
Heterozygous signal transducer and activator of transcription 
1 (STAT1) gain-of-function (GOF) mutations cause autoso-
mal dominant chronic mucocutaneous candidiasis (CMC) [1, 
2] but have also been associated with a much broader spec-
trum of infectious, inflammatory, vascular, and neoplastic 
manifestations [3–5]. These particular STAT1 mutations are 
considered GOF because of enhanced STAT1-dependent cel-
lular responses to cytokines, as evidenced by high levels of 
phosphorylated STAT1 (pSTAT1) molecules and high levels of 
STAT1-dependent downstream targets such as CXCL9 (MIG) 
and CXCL10 (IP-10) following interferon (IFN)-γ stimulation 
[2, 4]. Impaired production of Th17 cells has been implicated in 
the pathogenesis of CMC in these and other patients [1, 2, 5].
Others have used the Janus Kinase (JAK) inhibitor rux-
olitinib successfully for CMC and autoimmune phenomena 
in 3 patients with STAT1 GOF disease [6–8]. In contrast, we 
characterize ruxolitinib in vitro effects and describe ruxolitinib 
therapeutic failures in 2 STAT1 GOF patients with severe fungal 
infections other than CMC.
METHODS
Please refer to the online Supplementary Data.
RESULTS
We enrolled 6 patients with 5 different STAT1 GOF muta-
tions (3M, 3F, age range, 20–72  years) (Supplementary Table 
S1). Two of the 6 enrolled patients—patients 1 and 4—were 
treated with oral ruxolitinib. Fresh peripheral blood mono-
nuclear cells (PBMCs) from all 6 patients were used to study 
ruxolitinib’s in vitro effect on STAT1 GOF mutations. Patient 
1 (42-year-old man with STAT1 c.820C>T, p.R274W) suffered 
from severe dermatophytosis, with Trichophyton interdigitale 
and Trichophyton mentagrophytes, of both feet from childhood 
(patient 3 in [4]). He was treated in the past with itracona-
zole, fluconazole, voriconazole, posaconazole, amphotericin 
B (intravenous [IV] and topical), anidulafungin, and G-CSF, 
without cure. Because of persistent disease despite antifungals, 
ruxolitinib 20 mg orally twice daily was begun, in addition to an 
antifungal regimen of monthly 7 days IV anidulafungin treat-
ment and topical amphotericin B. Beside headache, the patient 
did not report any other side effects. After 4 weeks of treatment, 
his feet were worse in comparison with stable disease in the 
months before the initiation of ruxolitinib treatment, and rux-
olitinib was stopped (Figure 1A1–2).
Patient 4 (27-year-old woman with STAT1 c.1057G>A, 
p.E355K) had refractory, progressive disseminated coccidioido-
mycosis for more than 10 years, involving the brain, spine, lungs, 
liver, spleen, and adrenals (patient 1 in [5]). She was treated 
with fluconazole, itraconazole, voriconazole, posaconazole, 
and amphotericin B, without cure. She also received exogenous 
IFNγ, IFNα, S-adenosylmethionine, and interleukin (IL)-12, 
with appearance of new sites of disease in her liver, lung, and 
brain. At 25 years of age, she developed a new pleural effusion, 
increased pericardial effusion, and a pleural-based mass that 
encroached on the liver capsule. Oral ruxolitinib was begun and 
dosing was adjusted to normalization of STAT1 phosphoryla-
tion (Figure 1B1–3), eventually receiving 5 mg once daily. After 
5 months, she had new coccidioidomycosis in her left medial 
rectus muscle, and ruxolitinib was stopped.
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Figure 1. Skin lesions of patient 1 before treatment (A1) and after 4 weeks of oral ruxolitinib treatment (A2). (B) Ex vivo whole blood CD14+ cells pSTAT1 level in patient 
4 (red lines), at rest and up to 120’ after IFNγ stimulation, compared with 3 different healthy controls (blue lines). Assays were performed when the patient was ruxolitinib 
naïve (B1), treated with 20 mg ruxolitinib BID (B2), and treated with 10 mg ruxolitinib BID (B3). (C1) Patient 4’s (red bars) and a controls’ (n = 3, blue bars) CD14+ cells pSTAT1 
levels with IFNγ 15’ stimulation, with and without ruxolitinib pre-incubation at increasing concentrations. pSTAT1 levels are expressed in percentages of each individual’s 
STAT1 phosphorylation with IFNγ stimulation with no ruxolitinib pre-incubation. (C2) Patient 4’s (red bars) and a control’s (blue bars) CD14+ pSTAT1 levels at rest and with IFNγ 
stimulation, with and without ruxolitinib pre-incubation. IP-10 (D1) and MIG (D2) secretion level (pg/mL) of patients 4 and 5 (red bars) and healthy controls’ (n = 3; blue bars) 
PBMCs stimulated with IFNγ 400 U/mL for 24 hours, after pre-incubation with ruxolitinib at increasing concentrations. Abbreviation: AUC, area under the curve.
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We assessed the ability of ruxolitinib to alter pSTAT1 in freshly 
isolated PBMCs of healthy controls and STAT1 GOF patients. 
Ruxolitinib had a dose-dependent effect on STAT phospho-
rylation in CD14+ cells in both controls and patient 4 (Figures 
1C1–2). The half maximal inhibitory concentration (IC50) was 
50–100 nM in both patient 4 and controls (Figure 1C1); 50 nM 
of ruxolitinib normalized in vitro pSTAT1 levels in patient 4 
CD14+ cells (Figure 1C2), whereas 1000 nM completely blocked 
phosphorylation in both control and patient cells. 1000 nM rux-
olitinib similarly blocked STAT1 and STAT3 phosphorylation 
in CD4+, CD8+, and NK cells in response to IFNγ and IL-10 
stimulation, respectively (data not shown).
Patient 4’s median in vitro CD14+ cell peak pSTAT1 after 
IFNγ stimulation was 162% of normal (range, 131–189%; P, 
.0006) when she was ruxolitinib naive. We titrated her oral 
ruxolitinib dosage based on ex vivo pSTAT1 level after in vitro 
IFNγ-stimulation of CD14+ cells (Figure 1B). Two days prior to 
initiation of ruxolitinib, patient 4’s area under the curve (AUC) 
of STAT1 phosphorylation (geometric mean of fluorescence) vs 
time (minutes) in CD14+ cells was 2.2 times that of the control, 
and her peak pSTAT1 level was 1.4 times the healthy control. At 
20 mg ruxolitinib twice daily, her pSTAT1 AUC level was 63% of 
the control, and her peak phosphorylation was 51% of normal 
and delayed. Ruxolitinib 10 mg twice daily made her pSTAT1 
AUC similar to control (104%) with a normal peak pSTAT1. 
Ruxolitinib 5 mg once daily also made her pSTAT1 level similar 
to control (data not shown).
Because JAK inhibition affected pSTAT1 formation, we 
examined the ruxolitinib effect on downstream gene expres-
sion. We measured MIG and IP-10 levels in supernatants of 
IFNγ-stimulated PBMCs from STAT1 GOF patients and con-
trols, along with increasing concentrations of ruxolitinib (25–
1000 nM). Patients 4 and 5 had elevated IP-10 and MIG levels 
compared with controls (5.6× and 3.5× higher, respectively) 
(Figure 1D1–2). However, doses of ruxolitinib that led to nor-
malization of IFNγ-stimulated pSTAT1 levels did not normalize 
IFNγ-stimulated IP-10 or MIG secretion in patients 4 and 5. 
The amount of ruxolitinib required to normalize IP-10 secre-
tion from patients 4 and 5 PBMCs was 10× higher than that 
required to normalize pSTAT1 formation in patient 4’s CD14+ 
cells (50 vs 500 nM) (Figure 1D1). Paradoxically, in the low to 
medium concentration range (25–100 nM), in both controls 
and patients, ruxolitinib increased MIG secretion levels, but 
to a greater extent in the patients than controls (Figure 1D2). 
Only high concentrations (200/500 nM) of ruxolitinib could 
normalize MIG secretion in the PBMCs of patients 5 and 4, 
respectively.
We looked at the effect of ruxolitinib on IL-17 produc-
tion and Th17 cell number in patients 1 and 4.  Cells from 
patient 1 did not show any IL-17 production in response 
to C.  albicans, regardless of the presence of ruxolitinib in 
vitro, either at baseline or 2 weeks into ruxolitinib treatment. 
Patient 4’s baseline Th17 levels in PBMCs were compara-
ble with controls. On day 13 of treatment with ruxolitinib 
20 mg daily, IL-17A+ CD4+ T cells were 1.4%, and 3 months 
into treatment they were 1.7%, similar to controls (average 
of 3 controls, 1.55%; range, 1.34–1.84%). These levels were 
comparable with her Th17 levels prior to treatment (1.27%) 
[4]. We also asked whether ruxolitinib itself might impair 
Th17 function in our patients and controls. We stimulated 
the PBMCs of controls and 2 patients with CD3/CD28 anti-
bodies for 72 hours, along with increasing concentrations of 
ruxolitinib (0–1000  nM) and measured supernatant IL-17. 
Patients 4 and 6 produced lower levels of supernatant IL-17 
than controls (Supplementary Figure  1). Ruxolitinib had a 
dose-dependent negative effect on IL-17 secretion in both 
patients and controls.
We looked at the immune phenotypes of the patients 
(Supplementary Table S1). Patient 4 had low total lymphocytes, 
CD3+ lymphocytes, CD4+, and CD8+ T cells. Patients 3, 4, and 
6 had low NK cells. Patient 2 had low CD19+ cells. Patients 5 
and 6 had low IgA levels. Patient 4 had a nonprotective level of 
diphtheria antibodies.
DISCUSSION
Ruxolitinib did not improve the clinical condition of either of 
our 2 STAT1 GOF–treated patients, despite clear inhibition 
of STAT1 phosphorylation in cells from patients with STAT1 
GOF mutations. Despite the ability of ruxolitinib to normal-
ize the level of pSTAT1 in vitro and ex vivo, it did not nor-
malize the downstream activities of pSTAT1 at the doses used 
clinically. To achieve ruxolitinib normalization of chemokine 
production in vitro, levels of ruxolitinib may need to be much 
higher than those currently approved for use [9]. Extrapolating 
from pharmacokinetic data in healthy volunteers, achieving 
plasma levels of ruxolitinib above 500 nM might require oral 
doses as high as 100 mg twice daily, 5× higher than the cur-
rent maximum recommended dosage. Patient 4 was treated 
with posaconazole, which might inhibit ruxolitinib metabo-
lism by cytochrome P450 3A4, and thus may have increased 
ruxolitinib exposure in this specific patient [10]. It is possible 
that patient 4 was exposed to supra-therapeutic levels of ruxol-
itinib during the first weeks of therapy. However, we adjusted 
oral ruxolitinib dose to a level that normalized this patient’s ex 
vivo CD14+ pSTAT1 level, but did not suppress it below normal 
level. Ruxolitinib dosing was reduced first to 10 mg twice daily 
and eventually to 5 mg per day, meaning that the patient was 
treated with doses that were 50% to 12.5% of the daily-recom-
mended dose of 40 mg.
Two weeks of ruxolitinib treatment did not increase Th17 
number or IL-17 secretion in patient 1. Ruxolitinib also had a 
negative in vitro effect on IL-17 secretion from PBMCs of both 
patients and healthy controls, a possible concern for ruxolitinib 
therapy.
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The progression of infections during ruxolitinib treatment 
in our patients despite continued aggressive antifungal ther-
apy is of concern. Indeed, infections are possible complications 
of ruxolitinib therapy [11]. It is remarkable that severe CMC 
appears to respond so well to ruxolitinib therapy [6–8], which 
is in sharp contrast to our experience in severe or disseminated 
disease.
The immune defect and infection that were initially associ-
ated with GOF mutations were impaired Th17 immunity and 
CMC [1, 2]. However, there is a solid body of evidence that 
GOF mutations are associated with other infectious diseases and 
immune defects [3–5]. Sampaio et al. reported invasive fungal 
infections in 5 patients with GOF mutations [3]. In a cohort 
of 274 STAT1 GOF patients, CMC was observed in 98% of the 
patients [5]. However, the number of patients with documented 
Candida mucocutaneous infection was lower than the number 
of patients with documented viral infections: 140 (51%) vs 162 
(59%) patients, respectively. Ninety-nine (36%) of the patients 
had documented bacterial infections, 34 (12%) patients had 
documented invasive fungal infections, and 17 (6%) had doc-
umented mycobacterial infections. Of the tested patients in the 
same cohort, 19% had lymphopenia, 28% CD4 lymphopenia, 
16% CD8 lymphopenia, 19% low B cells, 49% low memory B 
cells, 25% low NK cells, 82% low CD3+ IL-17+ or CD4+IL-17+ 
cells, 32% low T cell proliferation, 38% low IgG2, and 50% low 
IgG4 [5]. Tabellini et al. demonstrated impaired NK cell function 
in GOF mutations [12]. In our cohort, 1 patient had low CD3+, 
CD4+, and CD8+ cells. Three patients had low NK cells. One 
patient had low B cells. Two other patients had low IgA levels.
The mechanisms behind STAT1 GOF immunodeficiency 
are not yet fully explained. However, it is reasonable to assume 
that the immune defects in GOF mutations are wider and more 
complicated than believed initially. Hence the increased suscep-
tibility of the majority of these patients to bacterial, viral, and 
fungal infections probably reflects broader impairment of the 
immune system than just Th17 immunity.
There are limited data on coccidiomycosis and primary 
immune deficiency (PID). Odio et  al. recognized 8 patients 
with PID among 370 cases of disseminated coccidiomyco-
sis [13]. Two had STAT3 loss-of-function mutations, 1 had 
IFN-γ receptor1 deficiency, 3 had IL-12 receptor loss-of-
function mutations, and 2 had STAT1 gain-of-function muta-
tions. These findings indicate that the IL-12/IFN-γ axis and 
STAT3-mediated immunity are central to protection against 
coccidiomycosis. Patient 4’s Th17 levels were normal prior 
to initiation of ruxolitinib treatment. Her CD4+, CD8+, and 
NK cells levels were low. The patient never had CMC, but she 
did have chronic dermatophytosis in childhood and young 
adulthood.
The failure to improve Th17 activity in our case (patient 
1)  and to fully recover it in previously published cases 
[6–8] implies that ruxolitinib may be exerting effects on 
mucocutaneous candidiasis through mechanisms other than 
or in addition toTh17. Ruxolitinib has a theoretical direct 
anticandida activity. Staurosporine, which is a nonspecific 
kinase inhibitor, was found to have direct and indirect anti-
candida activity [14–16]. Omura et al. demonstrated a direct 
anticandida activity of Staurosporine [14]. Lafayette et  al. 
demonstrated that Staurosporine enhanced the efficacy of 
antifungals targeting the cell wall, micafungin, and those tar-
geting the cell membrane, including fluconazole and the mor-
pholine fenpropimorph, which inhibits Erg2 and Erg24 [16]. 
Staurosporine also reduced azole resistance in clinical isolates 
[16]. We could not find similar evidence of staurosporine 
activity against coccidiomycosis.
The direct effect of JAK inhibitors on Candida has not 
been tested to the best of our knowledge. However, mouse 
models show conflicting data on the effect of JAK inhibi-
tors in invasive candidiasis [17, 18]. In 1 study, tofacitinib 
was associated with reduced survival [17]. In a different 
study, administration of ruxolitinib 50 mg/kg/d starting a 
day before Candida injection was associated with reduced 
survival, but administration of 6.25 mg/kg/d beginning on 
the second day of the infection was associated with increased 
survival [18]. Despite their relative specificity to JAK pro-
teins in humans, JAK inhibitors might have a similar effect 
as staurosporine in eukaryotes. This is an area that requires 
further research.
The mechanisms of CMC in STAT1 GOF are clearly asso-
ciated with impaired Th17 immunity. However, the critical 
final effectors of mucosal Candida immunity remain unclear. 
Other possible mechanisms that might account for the fre-
quent CMC in STAT1 GOF disease include IFNγ tachyphy-
laxis [4] and overexpression of chemokines and cytokines, 
leading to other forms of immune dysfunction [2, 3]. The dif-
ferences between our patients’ experiences with ruxolitinib 
and the relative successes reported in patients with CMC or 
autoimmunity may reflect that the immune defects that make 
patients susceptible to CMC are repaired by ruxolitinib, but 
the immune defects that lead to susceptibility to invasive fun-
gal disease are not. Our experience with a small number of 
patients is too limited to draw general conclusions about the 
role of ruxolitinib in STAT1 GOF disease. The reported ben-
efits of ruxolitinib in STAT1 GOF patients with either auto-
immune phenomena or mucosal candidiasis suggest that the 
underlying processes that govern invasive infections, autoim-
munity, and CMC in STAT1 GOF may not all be amenable to 
the same intervention.
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